---
title: "CITIC International slightly raised INNOVENT BIO's target price to 113.86 yuan, accelerating its transformation towards global biopharmaceuticals"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/281123712.md"
description: "CMB International released a research report, expecting INNOVENT BIO to achieve strong performance in the fiscal year 2025, with a net profit of RMB 834 million and total revenue of RMB 13 billion, a year-on-year increase of 38%. Product sales are expected to reach RMB 11.9 billion, a year-on-year increase of 45%. Based on INNOVENT BIO's innovation capabilities and global development potential, the rating is maintained at \"Buy,\" with the target price slightly raised from HKD 110.62 to HKD 113.86"
datetime: "2026-03-31T04:26:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281123712.md)
  - [en](https://longbridge.com/en/news/281123712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281123712.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/281123712.md) | [繁體中文](https://longbridge.com/zh-HK/news/281123712.md)


# CITIC International slightly raised INNOVENT BIO's target price to 113.86 yuan, accelerating its transformation towards global biopharmaceuticals

Zhaoyin International published a research report indicating that INNOVENT BIO (01801.HK) will have strong performance in the fiscal year 2025, recording a net profit of RMB 834 million for the first time. During the period, total revenue reached RMB 13 billion, a year-on-year increase of 38%; product sales reached RMB 11.9 billion, a year-on-year increase of 45%. Given INNOVENT BIO's strong product line innovation capabilities and global development potential, accelerating its transformation into a global biopharmaceutical company, the "Buy" rating for INNOVENT BIO is maintained, with the target price slightly raised from HKD 110.62 to HKD 113.86

### 相关股票

- [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-CN/quote/589720.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md)
- [INNOVENT BIO (01801.HK)](https://longbridge.com/zh-CN/quote/01801.HK.md)
- [Guotai CSI Hugangshen Innovative Drugs Industry ETF (517110.CN)](https://longbridge.com/zh-CN/quote/517110.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-CN/quote/560600.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)

## 相关资讯与研究

- [Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD](https://longbridge.com/zh-CN/news/280236866.md)
- [Innovent Biologics posts FY profit RMB813.6 million](https://longbridge.com/zh-CN/news/280626112.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-CN/news/281662341.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-CN/news/281458440.md)
- [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-CN/news/281501537.md)